Amphastar Pharmaceuticals, Inc. Reports Financial Results For The Three Months Ended June 30, 2016
RANCHO CUCAMONGA, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2016.
Second Quarter Highlights
* Net revenues of $68.0 million for the second quarter
* GAAP net income of $6.9 million, or $0.15 per diluted share for the second quarter
* Adjusted non-GAAP net income of $10.3 million, or $0.23 per diluted share for the second quarter
Dr. Jack Zhang, Amphastar’s CEO, commented: “Resubmitting our Primatene® NDA this quarter is a big milestone for the company and its inhalation platform. We look forward to the possibility of bringing this product back to the market in early 2017.”
Second Quarter Highlights
* Net revenues of $68.0 million for the second quarter
* GAAP net income of $6.9 million, or $0.15 per diluted share for the second quarter
* Adjusted non-GAAP net income of $10.3 million, or $0.23 per diluted share for the second quarter
Dr. Jack Zhang, Amphastar’s CEO, commented: “Resubmitting our Primatene® NDA this quarter is a big milestone for the company and its inhalation platform. We look forward to the possibility of bringing this product back to the market in early 2017.”